Literature DB >> 10614667

Retardation in bone resorption after bone marrow ablation in klotho mutant mice.

T Yamashita1, H Yoshitake, K Tsuji, N Kawaguchi, Y Nabeshima, M Noda.   

Abstract

The klotho gene mutant mice exhibit both osteopetrotic phenotype, including elongation of trabeculae in the epiphyses of long bones and vertebral bodies, and osteopenic phenotype, such as thin cortical bones in the diaphyses of these bones. These diverse features raise the question of whether the klotho gene defect results in alteration in bone resorption in vivo. Therefore, we examined the effect of the klotho gene defect on bone resorption by using bone marrow ablation model. At 1 week after bone marrow ablation, trabecular bones were formed in the ablated marrow cavity to levels higher than those in unablated bones in both klotho mutant and wild-type mice. At 2 weeks postsurgery, newly formed trabecular bones were resorbed in wild-type mice to resume normal bone marrow and trabecular bone volume fraction as reported previously. In contrast, the newly formed trabecular bones in the ablated marrow in klotho mutant mice remained at levels similar to those at 1 week. The defect in the bone resorption phase in klotho mutant mice is associated with site-specific reduction of the number and size of osteoclasts in klotho mutant mice. Moreover, the expression levels of osteoprotegerin messenger RNA in the ablated femora of klotho mutant mice were higher than those in wild-type mice. These results indicate that lack of klotho gene expression suppressed bone resorption that should normally take place 2 weeks after bone marrow ablation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10614667     DOI: 10.1210/endo.141.1.7252

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  9 in total

Review 1.  Role of αKlotho and FGF23 in regulation of type II Na-dependent phosphate co-transporters.

Authors:  Ming Chang Hu; Mingjun Shi; Orson W Moe
Journal:  Pflugers Arch       Date:  2018-12-01       Impact factor: 3.657

Review 2.  Potential application of klotho in human chronic kidney disease.

Authors:  Javier A Neyra; Ming Chang Hu
Journal:  Bone       Date:  2017-01-20       Impact factor: 4.398

Review 3.  Effects of klotho deletion from bone during chronic kidney disease.

Authors:  Jovana Kaludjerovic; Hirotaka Komaba; Beate Lanske
Journal:  Bone       Date:  2017-02-20       Impact factor: 4.398

4.  Deletion of mitogen-activated protein kinase phosphatase 1 modifies the response to mechanical bone marrow ablation in a mouse model.

Authors:  Jodi Carlson; Qing Zhang; Anton Bennett; Agnès Vignery
Journal:  Comp Med       Date:  2009-06       Impact factor: 0.982

5.  Histological and elemental analyses of impaired bone mineralization in klotho-deficient mice.

Authors:  Hironobu Suzuki; Norio Amizuka; Kimimitsu Oda; Masaki Noda; Hayato Ohshima; Takeyasu Maeda
Journal:  J Anat       Date:  2008-01-30       Impact factor: 2.610

6.  High-throughput screening of mouse gene knockouts identifies established and novel skeletal phenotypes.

Authors:  Robert Brommage; Jeff Liu; Gwenn M Hansen; Laura L Kirkpatrick; David G Potter; Arthur T Sands; Brian Zambrowicz; David R Powell; Peter Vogel
Journal:  Bone Res       Date:  2014-10-28       Impact factor: 13.567

7.  2,3,5,4'-Tetrahydroxystilbene-2-O-β-D-glucoside Promotes Expression of the Longevity Gene Klotho.

Authors:  Shuang Ling; Ju Duan; Rongzhen Ni; Jin-Wen Xu
Journal:  Oxid Med Cell Longev       Date:  2016-11-03       Impact factor: 6.543

Review 8.  The controversy of klotho as a potential biomarker in chronic kidney disease.

Authors:  Li-Xia Yu; Sha-Sha Li; Min-Yue Sha; Jia-Wei Kong; Jian-Ming Ye; Qi-Feng Liu
Journal:  Front Pharmacol       Date:  2022-09-21       Impact factor: 5.988

Review 9.  Klotho: a humeral mediator in CSF and plasma that influences longevity and susceptibility to multiple complex disorders, including depression.

Authors:  M G Pavlatou; A T Remaley; P W Gold
Journal:  Transl Psychiatry       Date:  2016-08-30       Impact factor: 6.222

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.